Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — you cannot start Wegovy at 1mg. The licensed UK starting dose is 0.25mg once weekly, a lower dose designed to let your body adjust before any step upward. The 1mg dose sits partway along a five-rung titration ladder, and reaching it requires two prior increases under prescriber supervision. These medicines are prescription-only, so the schedule your prescriber sets is the one that governs your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A common assumption is that Wegovy's 1mg dose is close enough to the beginning that starting there is harmless, perhaps even more efficient. It isn't. The dose ladder exists for a physiological reason, not a bureaucratic one. Semaglutide slows gastric emptying and changes how your gut responds to food. Introduce too much of it too quickly and the gastrointestinal side effects (nausea in particular, but also vomiting, diarrhoea and reflux) can be severe enough to stop treatment altogether. Starting at 0.25mg for four weeks gives your system a genuine settling-in period before any increase.
The 1.0mg dose is the third position on a five-step titration schedule. By the time a patient on Wegovy reaches 1mg, they have already spent around eight weeks on lower doses. That progression isn't arbitrary; it reflects the way the prescribing guidance, the SmPC and the NHS's own patient information on semaglutide are written. Jumping to 1mg from nothing removes that buffer entirely.
People sometimes confuse Wegovy's titration path with that of Ozempic, the diabetes-licensed form of semaglutide, which does begin at 0.25mg but moves through different maintenance doses for a different clinical purpose. The two are not interchangeable, and Wegovy is the only semaglutide licensed for weight management in the UK, not Ozempic, not Rybelsus.
The full UK titration sequence for Wegovy is 0.25mg for four weeks, then 0.5mg for four weeks, then 1.0mg for four weeks, then 1.7mg for four weeks, then 2.4mg as the standard maintenance dose. Some patients titrate more slowly if side effects arise at a given level, that call belongs to the prescriber, not the schedule printed on a webpage.
The 1.0mg step, when patients reach it, is often the point where appetite suppression becomes more noticeable. Some people find the transition to 1mg produces a brief return of mild nausea; those who skipped the lower steps would have no tolerance built up at all. You can read more about how each dose fits into the broader picture on the Wegovy dose guide.
From a clinical standpoint, a prescriber reviewing your case would have no basis to approve a starting dose of 1mg. The licensed indication specifies the titration schedule, and deviating from it requires clinical justification, not a patient preference for speed. It is also worth knowing that the 0.5mg step, which sits just below 1mg, has its own clinical logic; the question of starting at 0.5mg comes up for similar reasons and gets the same answer.
The first four weeks on 0.25mg are sometimes called the tolerability phase, because that is precisely what they are, a period for your body to adjust rather than for measurable weight loss to begin. Patients who expect dramatic results in week one are often disappointed; the design of the schedule means weight loss becomes more meaningful once maintenance doses are reached. That framing matters, because it sets realistic expectations from day one.
Side effects, if they occur, tend to be most noticeable in the early weeks and after each dose increase. The NHS medicines page for semaglutide lists the common ones: nausea, diarrhoea, constipation, indigestion and fatigue. Most people find these settle within a week or two of each step up. A prescriber who reviews your progress before each dose increase (as happens at nume, where a clinician reads your notes before every repeat) can slow the titration if your body needs more time.
If you are curious about the end of the titration path, there is now a higher maintenance option: the MHRA approved a 7.2mg dose of Wegovy in early 2026, initially supplied as three 2.4mg pens per week, with a dedicated single-dose pen approved that April. If you are wondering whether it is possible to begin treatment at the 2.4mg maintenance dose, the short answer is no, reaching it still requires the same gradual escalation from 0.25mg. For a full picture of how pricing fits into the decision to start, the Wegovy cost overview lays out what a private prescription typically involves.
Because Wegovy is a prescription-only medicine, the only legitimate route to it is a clinical assessment followed by a prescription from a registered prescriber. There is no shortcut that skips that step and remains legal or safe. A prescriber will establish the dose that is right for your health profile (starting at 0.25mg for almost everyone) and will review your progress before each change.
At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber. If you order by midday on a working day and are approved as clinically suitable, treatment is dispatched the same day and delivered free the next working day by DPD, in plain packaging. Our clinical approach is explained on the about page, and you can see what the weight-loss treatment options look like before you begin. A question our prescribers hear regularly: is 1mg a safe place to start? The answer is the same every time, no, and here is the schedule that is.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.